Category: Corporate NewsBy Rameda AdminAugust 13, 2024 Author: Rameda Admin Post navigationPreviousPrevious post:Rameda Announces Price Increase Approvals for All Its Top ProductsNextNext post:Rameda Announces the Establishment of Glow: A Strategic Expansion into the Thriving Freely Priced Cosmeceutical MarketRelated PostsRameda Announces the Establishment of Glow: A Strategic Expansion into the Thriving Freely Priced Cosmeceutical MarketSeptember 9, 2024Rameda Announces Price Increase Approvals for All Its Top ProductsAugust 7, 2024Rameda Expands Freely Priced Portfolio with Launch of Ramelact, Egypt’s First Lactase Enzyme Supplement for the treatment of Lactose IntoleranceMay 28, 2024Rameda 4Q23 Earnings ReleaseMarch 20, 2024Rameda Maintains its Impressive Momentum with the Launch of a New Type 2 Diabetes Product, Bolstering its Chronic PortfolioNovember 28, 2023Rameda Reports its 3Q23 ResultsNovember 14, 2023
Rameda Announces the Establishment of Glow: A Strategic Expansion into the Thriving Freely Priced Cosmeceutical MarketSeptember 9, 2024
Rameda Expands Freely Priced Portfolio with Launch of Ramelact, Egypt’s First Lactase Enzyme Supplement for the treatment of Lactose IntoleranceMay 28, 2024
Rameda Maintains its Impressive Momentum with the Launch of a New Type 2 Diabetes Product, Bolstering its Chronic PortfolioNovember 28, 2023
